Evofem Biosciences, Inc.

Evofem Biosciences, Inc. insiders are currently net buyers of EVFM stock, showing neutral sentiment over the past 90 days. Executives have purchased $54.9M while selling $32.8M, resulting in a positive net flow of $22.1M. This buying activity represents 63% of total transaction volume.

Evofem Biosciences, Inc. has 15 active insiders who have filed SEC Form 4 transactions in the past 90 days. Biopharma, Inc. Pdl (Executive) leads with 2 transactions totaling $30.0M. Research Corp Acacia (Executive) follows with 1 transactions worth $29.3M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Evofem Biosciences, Inc.'s current score of 63/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $54.9M in purchases versus $32.8M in sales.

The most recent insider transaction occurred on Jan 12, 2024, when Zhang Yan (Executive) disposed of 104 shares at $0.04 per share for $4. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, EVFM insider trading sentiment is currently neutral with an Alignment Score of 63/100. The net insider flow of $22.1M reflects accumulation, with 63% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Evofem Biosciences, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At EVFM, we track all Form 4 filings—currently showing 153 transactions from 15 insiders over 90 days.

A 10b5-1 plan allows Evofem Biosciences, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At EVFM, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at EVFM appears discretionary, making insider signals more meaningful.

You can monitor Evofem Biosciences, Inc. (EVFM) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 15 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Evofem Biosciences, Inc.'s current score of 63/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $54.9M in purchases versus $32.8M in sales over 90 days, resulting in a net flow of $22.1M.

SEC Form 4 filings are mandatory reports that Evofem Biosciences, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At EVFM, the most common type is "P" with 22 occurrences. The most recent Form 4 was filed on Jan 12, 2024 by Zhang Yan.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Evofem Biosciences, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at EVFM represents discretionary decisions with more informational value.